glp 1 agonist cardiovascular outcomes and mortality with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Key cardiovascular outcomes results for

On the other hand a different study found that elevated MMP-3 levels, among other markers, at disease onset were associated with achieving sustained disease-modifying antirheumatic drug-free remission in ACPA-negative patients

10.3892/ol.2020.12332 96 ImaiH.HakkakuN.IwamotoR.SuzukiJ.SuzukiT.TajimaY.et al (2009)

Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A alpha-chain gene are not associated with the decay of the mutant mRNAs

A 2015 review by Verdin (Gladstone Institutes / UCSF), published in Science , established that cellular NAD+ concentrations change during aging and that modulation of NAD+ usage or production can prolong both healthspan and lifespan